Alkeon Capital Management - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 257 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.

Quarter-by-quarter ownership
Alkeon Capital Management ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$69,297,005
-22.7%
1,943,8150.0%0.12%
-21.0%
Q2 2023$89,668,186
+21.2%
1,943,815
+5.3%
0.16%
-3.7%
Q1 2023$74,011,527
-13.9%
1,845,674
-0.5%
0.16%
-50.9%
Q4 2022$85,910,970
-6.2%
1,854,327
-16.2%
0.33%
+12.2%
Q3 2022$91,597,000
-37.8%
2,211,959
-10.4%
0.30%
-25.3%
Q2 2022$147,248,000
-14.4%
2,468,130
+4.2%
0.40%
+14.8%
Q1 2022$171,973,000
-11.4%
2,368,130
+2.6%
0.34%
-3.9%
Q4 2021$194,091,000
-6.8%
2,308,1300.0%0.36%
+2.3%
Q3 2021$208,170,000
+14.1%
2,308,130
+20.6%
0.35%
+30.5%
Q2 2021$182,467,000
+22.0%
1,913,648
+45.7%
0.27%
+21.2%
Q1 2021$149,595,000
-17.6%
1,313,857
+0.2%
0.22%
-24.7%
Q4 2020$181,460,000
+17.5%
1,310,845
-30.2%
0.30%
+3.1%
Q3 2020$154,453,000
+11.0%
1,879,220
+5.6%
0.29%
-18.8%
Q2 2020$139,171,000
+93.3%
1,779,220
+9.8%
0.35%
+14.7%
Q1 2020$72,000,000
+22.1%
1,620,533
+17.4%
0.31%
+39.5%
Q4 2019$58,962,000
-13.1%
1,380,533
-13.0%
0.22%
-7.9%
Q3 2019$67,880,000
-27.4%
1,586,733
+7.8%
0.24%
-35.4%
Q2 2019$93,455,000
-8.4%
1,471,7330.0%0.37%
-27.3%
Q1 2019$102,080,000
+186.5%
1,471,733
+79.6%
0.51%
+119.4%
Q4 2018$35,633,000
-37.0%
819,526
+10.5%
0.23%
-13.4%
Q3 2018$56,592,000
+49.8%
741,321
+50.9%
0.27%
+52.3%
Q2 2018$37,766,000491,2960.18%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q1 2021
NameSharesValueWeighting ↓
First Light Asset Management, LLC 441,159$39,788,0002.62%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 103,100$9,286,0002.24%
Rock Springs Capital Management LP 801,109$72,252,0001.52%
Avidity Partners Management LP 455,000$41,036,0000.91%
Motley Fool Asset Management LLC 134,357$12,118,0000.79%
FEDERATED HERMES, INC. 3,987,032$359,590,0000.68%
EMERALD ADVISERS, LLC 196,124$17,688,0000.64%
Ergoteles LLC 128,100$11,553,0000.42%
Tekla Capital Management LLC 140,726$12,692,0000.41%
Beck Bode, LLC 14,990$1,352,0000.38%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders